XML 84 R54.htm IDEA: XBRL DOCUMENT v3.24.1.u1

SIGNIFICANT AGREEMENTS AND CONTRACTS - Additional Information (Details) - USD ($)				1 Months Ended									3 Months Ended						6 Months Ended		9 Months Ended		12 Months Ended
	Jul. 26, 2022	Mar. 31, 2021	Sep. 03, 2019	Apr. 22, 2024	Dec. 31, 2023	Sep. 30, 2023	Mar. 31, 2023	Aug. 31, 2022	Mar. 31, 2022	Dec. 31, 2021	May 31, 2021	Sep. 30, 2019	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2023	Dec. 31, 2022	Nov. 30, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue													$ 11,250,000	$ 7,497,000	$ 26,107,000	$ 40,744,000	$ 6,216,000	$ 7,269,000	$ 33,604,000	$ 13,485,000	$ 44,854,000	$ 54,229,000	$ 59,570,000	$ 64,448,000
Capitalized contract cost, expense															475,000			0	40,000	0	53,000	1,772,000	77,000	0
Accounts receivable					$ 16,246,000	$ 3,178,000	$ 26,121,000		$ 8,783,000				$ 3,178,000	$ 5,483,000	$ 26,121,000	$ 5,042,000	$ 4,833,000	$ 8,783,000	$ 5,483,000	$ 4,833,000	$ 3,178,000	$ 5,042,000	16,246,000	5,833,000
Mundipharma Medical Company | Related Party
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement, cost sharing percentage (as a percent)			50.00%
Collaborative agreement, maximum cost share			$ 31,200,000																				31,200,000
Collaborative agreement, potential transaction value			$ 568,400,000
Payments related to collaborative agreement																							30,000,000
Accounts receivable					13,900,000																		13,900,000	200,000
Mundipharma Medical Company | Related Party | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue, remaining performance obligation, amount					$ 11,500,000																		$ 11,500,000
Revenue, remaining performance obligation, expected timing of satisfaction, period (in years)					2 years																		2 years
Mundipharma Medical Company | Related Party | Milestone Achievement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue					$ 11,100,000			$ 11,100,000		$ 2,800,000													$ 25,100,000
Revenue from collaborative arrangement, excluding revenue from contract with customer, uncredited portion					10,100,000																		10,100,000
Mundipharma Medical Company | Related Party | Milestone Achievement | Subsequent event
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue				$ 2,800,000
Mundipharma Medical Company | Related Party | License Of Intellectual Property
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue												$ 17,900,000
Revenue from collaborative arrangement, excluding revenue from contract with customer, noncurrent liability																									$ 11,100,000
Mundipharma Medical Company | Related Party | Royalties
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue																							0	0
Janssen Pharmaceuticals, Inc. | Related Party
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative agreement, maximum cost share																							49,800,000
Payments related to collaborative agreement																							27,000,000
Collaborative arrangement, termination provisions, required period of written notice (in days)		90 days
Accounts receivable					1,900,000																		1,900,000	5,600,000
Janssen Pharmaceuticals, Inc. | Related Party | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue, remaining performance obligation, amount					$ 3,800,000																		$ 3,800,000
Revenue, remaining performance obligation, expected timing of satisfaction, period (in years)					6 months																		6 months
Janssen Pharmaceuticals, Inc. | Related Party | Upfront Payment
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payments related to collaborative agreement		$ 27,000,000
Janssen Pharmaceuticals, Inc. | Related Party | R&D Funding
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative agreement, potential transaction value		58,200,000
Janssen Pharmaceuticals, Inc. | Related Party | Development, Regulatory, and Commercial Milestones
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative agreement, potential transaction value		$ 695,000,000
Janssen Pharmaceuticals, Inc. | Related Party | Milestone Achievement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue						$ 7,000,000			$ 3,000,000														$ 10,000,000
Janssen Pharmaceuticals, Inc. | Related Party | License Of Intellectual Property
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue											$ 26,800,000
Janssen Pharmaceuticals, Inc. | Related Party | Royalties
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue																							0	0
Melinta Therapeutics Inc | License Of Intellectual Property
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Capitalized contract cost, gross					$ 2,000,000																		2,000,000
Capitalized contract cost, expense																							500,000	1,800,000
Capitalized contract cost, net					200,000																		200,000
Melinta Therapeutics Inc | Milestone Achievement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Capitalized contract cost, gross					500,000																		500,000
Melinta Therapeutics Inc | Related Party
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative agreement, potential transaction value	$ 460,000,000
Payments related to collaborative agreement																							30,000,000
Accounts receivable					400,000																		400,000
Melinta Therapeutics Inc | Related Party | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue, remaining performance obligation, amount					$ 3,700,000																		$ 3,700,000
Revenue, remaining performance obligation, expected timing of satisfaction, period (in years)					2 years																		2 years
Melinta Therapeutics Inc | Related Party | Upfront Payment
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payments related to collaborative agreement	30,000,000
Melinta Therapeutics Inc | Related Party | Development, Regulatory, and Commercial Milestones
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative agreement, potential transaction value	$ 430,000,000
Melinta Therapeutics Inc | Related Party | Milestone Achievement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue							$ 20,000,000																$ 20,000,000
Melinta Therapeutics Inc | Related Party | License Of Intellectual Property
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue								$ 25,900,000
Melinta Therapeutics Inc | Related Party | Royalties
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue																							$ 200,000	$ 0

X

- Definition

Collaborative Arrangement, Cost Sharing Percentage

+ References

No definition available.

+ Details

Name:	cdtx_CollaborativeArrangementCostSharingPercentage
Namespace Prefix:	cdtx_
Data Type:	dtr-types1:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Collaborative Arrangement, Maximum Third Party Share Of Cost

+ References

No definition available.

+ Details

Name:	cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost
Namespace Prefix:	cdtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Collaborative Arrangement, Termination Provisions, Required Period Of Written Notice

+ References

No definition available.

+ Details

Name:	cdtx_CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice
Namespace Prefix:	cdtx_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Collaborative Arrangement, Transaction, Potential Value

+ References

No definition available.

+ Details

Name:	cdtx_CollaborativeArrangementTransactionPotentialValue
Namespace Prefix:	cdtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Payments Related To Collaborative Agreements

+ References

No definition available.

+ Details

Name:	cdtx_PaymentsRelatedToCollaborativeAgreements
Namespace Prefix:	cdtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Noncurrent Liability

+ References

No definition available.

+ Details

Name:	cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability
Namespace Prefix:	cdtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer, Uncredited Portion

+ References

No definition available.

+ Details

Name:	cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerUncreditedPortion
Namespace Prefix:	cdtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 310
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481990/310-10-45-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 310
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481990/310-10-45-9

+ Details

Name:	us-gaap_AccountsReceivableNetCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 340
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479483/340-40-50-3

+ Details

Name:	us-gaap_CapitalizedContractCostAmortization
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Amount, before accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 340
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479483/340-40-50-3

+ Details

Name:	us-gaap_CapitalizedContractCostGross
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 340
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479483/340-40-50-3

+ Details

Name:	us-gaap_CapitalizedContractCostNet
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479402/808-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 3
-SubTopic 10
-Topic 808
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479428/808-10-45-3

+ Details

Name:	us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Amount of transaction price allocated to performance obligation that has not been recognized as revenue.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (a)
-SubTopic 10
-Topic 606
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-13

+ Details

Name:	us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)(1)
-SubTopic 10
-Topic 606
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-13

+ Details

Name:	us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	instant

X

- Details

Name:	srt_CounterpartyNameAxis=cdtx_MundipharmaMedicalCompanyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2024-01-01
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=cdtx_MilestoneAchievementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=cdtx_LicenseOfIntellectualPropertyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=us-gaap_RoyaltyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=cdtx_JanssenPharmaceuticalsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=cdtx_UpfrontPaymentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=cdtx_RDFundingMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=cdtx_DevelopmentRegulatoryAndCommercialMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=cdtx_MelintaTherapeuticsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_CapitalizedContractCostAxis=cdtx_LicenseOfIntellectualPropertyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_CapitalizedContractCostAxis=cdtx_MilestoneAchievementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: